Antibody–drug conjugate (ADC) is typically composed of a monoclonal antibody (mAbs)
covalently attached to a cytotoxic drug via a chemical linker. It combines both the …

As distinct cancer biomarkers have been discovered in recent years, a need to reclassify
tumors by more than their histology has been proposed, and therapies are now tailored to …

Over the past 5 years, improvements in the design of antibody–drug conjugates (ADCs)
have enabled major advances that have reshaped the treatment of several advanced-stage …

Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
- Annals of Oncology Skip to Main Content Advertisement Annals of Oncology European …

The last 25 years have seen significant growth in new therapeutic options for breast cancer,
termed targeted therapies based on their ability to block specific pathways known to drive …

Simple Summary HER2-positive breast cancer (BC), which accounts for~ 20% of BC, is one
of the more aggressive and has the worst overall survival rate among them. These patients …

Abstract Antibody–drug conjugates (ADCs), a class of targeted cancer therapeutics
combining monoclonal antibodies with a cytotoxic payload via a chemical linker, have …

This manuscript describes the Advanced Breast Cancer (ABC) international consensus
guidelines updated at the last two ABC international consensus conferences (ABC 6 in …

Antibody–drug conjugates (ADCs) represent a novel and evolving class of antineoplastic
agents, constituted by monoclonal antibody linked to biologically active drugs, delivering …

Antibody-drug conjugates (ADCs) represent an important class of cancer therapies that have
revolutionized the treatment paradigm of solid tumors. To date, many ongoing studies of …